Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M

Alkermes plc.

2023-FY EPS reported $2.10 revenue$1,663,405,000

GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.
Proprietary net sales $920M (+18% YoY); LYBALVI grew to $191.9M (up 100% YoY).
2024 guidance: total rev $1.5-1.6B, GAAP net income $350-390M, non-GAAP net income $465-505M.
Board approved new $400M share repurchase program (no expiration date).
Oncology separation completed Nov 2023; Athlone facility sale to Novo Nordisk for $92.5M expected mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alkermes plc. reported the quarter and year ended Dec. 31, 2023 results: revenue $1,663.4 million, net income $355.8 million, EPS $2.10. Guidance initiated.

Period: the quarter and year ended Dec. 31, 2023
Revenue: $1,663.4 million
Net income: $355.8 million
EPS: $2.10
Guidance: initiated
Result: reported results

Exact text from the filing

Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2.10 for 2023 —

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0000950170-24-015597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.